1. Home
  2. SFHG vs CMMB Comparison

SFHG vs CMMB Comparison

Compare SFHG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SFHG

Samfine Creation Holdings Group Limited Ordinary Share

HOLD

Current Price

$0.69

Market Cap

11.6M

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$2.08

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFHG
CMMB
Founded
1993
2004
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Publishing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
13.8M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
SFHG
CMMB
Price
$0.69
$2.08
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
631.5K
93.1K
Earning Date
10-30-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,577,200.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.56
N/A
52 Week Low
$0.32
$2.21
52 Week High
$2.32
$9.84

Technical Indicators

Market Signals
Indicator
SFHG
CMMB
Relative Strength Index (RSI) 73.53 32.06
Support Level $0.55 $2.44
Resistance Level $0.59 $2.77
Average True Range (ATR) 0.06 0.20
MACD 0.03 -0.03
Stochastic Oscillator 91.79 5.08

Price Performance

Historical Comparison
SFHG
CMMB

About SFHG Samfine Creation Holdings Group Limited Ordinary Share

Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: